RT Journal Article
SR Electronic
T1 <em>MARK2</em> variants cause autism spectrum disorder <em>via</em> the downregulation of WNT/β-catenin signaling pathway
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.24.24304501
DO 10.1101/2024.04.24.24304501
A1 Gong, Maolei
A1 Li, Jiayi
A1 Liu, Yijun
A1 Wilke, Matheus Vernet Machado Bressan
A1 Li, Qian
A1 Liu, Haoran
A1 Liang, Chen
A1 Morales-Rosado, Joel A
A1 Cohen, Ana S.A.
A1 Hughes, Susan S.
A1 Sullivan, Bonnie R.
A1 Waddell, Valerie
A1 van den Boogaard, Marie-José H.
A1 van Jaarsveld, Richard H.
A1 van Binsbergen, Ellen
A1 van Gassen, Koen L
A1 Wang, Tianyun
A1 Hiatt, Susan M.
A1 Amaral, Michelle D.
A1 Kelley, Whitley V.
A1 Zhao, Jianbo
A1 Feng, Weixing
A1 Ren, Changhong
A1 Yu, Yazhen
A1 Boczek, Nicole J
A1 Ferber, Matthew J.
A1 Lahner, Carrie
A1 Elliott, Sherr
A1 Ruan, Yiyan
A1 Cyril, Mignot
A1 Keren, Boris
A1 Xie, Hua
A1 Wang, Xiaoyan
A1 Popp, Bernt
A1 Zweier, Christiane
A1 Piard, Juliette
A1 Coubes, Christine
A1 Mau-Them, Frederic Tran
A1 Safraou, Hana
A1 Innes, Micheil
A1 Gauthier, Julie
A1 Michaud, Jacques
A1 Koboldt, Daniel C.
A1 Sylvie, Odent
A1 Willems, Marjolaine
A1 Tan, Wen-Hann
A1 Cogne, Benjamin
A1 Rieubland, Claudine
A1 Braun, Dominique
A1 McLean, Scott Douglas
A1 Platzer, Konrad
A1 Zacher, Pia
A1 Oppermann, Henry
A1 Evenepoel, Lucie
A1 Blanc, Pierre
A1 Khattabi, Laïla El
A1 Haque, Neshatul
A1 Dsouza, Nikita R.
A1 Zimmermann, Michael T.
A1 Urrutia, Raul
A1 Klee, Eric W
A1 Shen, Yiping
A1 Du, Hongzhen
A1 Qin, Zailong
A1 Liu, Chang-Mei
A1 Chen, Xiaoli
YR 2024
UL http://medrxiv.org/content/early/2024/04/25/2024.04.24.24304501.abstract
AB MARK2, a member of the evolutionarily conserved PAR1/MARK serine/threonine kinase family, has been identified as a novel risk gene for autism spectrum disorder (ASD) based on the enrichment of de novo loss-of-function (Lof) variants in large-scale sequencing studies of ASD individuals. However, the features shared by affected individuals and the molecular mechanism of MARK2 variants during early neural development remained unclear. Here, we report 31 individuals carrying heterozygous MARK2 variants and presenting with ASD, other neurodevelopmental disorders, and typical facial dysmorphisms. Lof variants predominate (81%) in affected individuals, while computational analysis and in vitro transfection assay also point to MARK2 loss resulting from missense variants. Using patient-derived and CRISPR-engineered isogenic induced pluripotent stem cells (iPSCs), and Mark2+/- (HET) mice, we show that MARK2 loss leads to systemic neurodevelopmental deficits, including anomalous polarity in neural rosettes, imbalanced proliferation and differentiation in neural progenitor cells (NPCs), abnormal cortical development and ASD-like behaviors in mice. Further using RNA-Seq and lithium treatment, we link MARK2 loss to the downregulated WNT/β-catenin signaling pathway and identify lithium as a potential drug for treating MARK2-related ASD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Key Research and Development Program of China (project (2021YFA1101402/2018YFA0108001), the Strategic Priority Research Program of the Chinese Academy of Sciences (No. XDA16010300/XDA16021400) and the Open Project Program of the State Key Laboratory of Stem Cell and Reproductive Biology. This study was also supported by grants from the National Science Foundation of China (82371868 and 31900690), Beijing Natural Science Foundation (7202019), Research Foundation of Capital Institute of Pediatrics (CXYJ-2021006) and Guangxi Science and Technology Program Project (Guike AB17195011).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committees of the respective institutions, including the Capital Institute of Pediatrics (SHERLL202001), Mayo Clinic (IRB#19-003389) and Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region (2017-3-11).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes